IPMN: surgical treatment

Käppeli, Reto M.; Müller, Sascha; Hummel, Bianka; Kruse, Christina; Müller, Philip; Fornaro, Jürgen; Wilhelm, Alexander; Zadnikar, Marcel; Schmied, Bruno M.; Tarantino, Ignazio

doi:10.1007/s00423-013-1106-1

Cited by 16 publications

(9 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent reports show that preventive surgery is recommended for MD‐type IPMNs due to the high risk of malignant transformation (on average 70%). On the other hand, the management of BD‐type IPMNs remains debated as estimated risk of malignancy varies between 6% and 46% . Routine cross‐sectional imaging such as ultrasound imaging (US), multidetector computed tomography (CT), and magnetic resonance imaging (MRI) have been frequently used to detect and diagnose IPMNs .…”

Section: Introductionmentioning

confidence: 99%

Proteome characterization of human pancreatic cyst fluid from intraductal papillary mucinous neoplasm by liquid chromatography/tandem mass spectrometry

Park

Han

et al. 2017

Rapid Comm Mass Spectrometry

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Proteome characterization of human pancreatic cyst fluid from intraductal papillary mucinous neoplasm by liquid chromatography/tandem mass spectrometry

Park

Han

et al. 2017

Rapid Comm Mass Spectrometry

View full text Add to dashboard Cite

show abstract

“…IPMNs have the potential for malignancy. IPMN of pancreas is defined as mucin producing cystic neoplasms with intraductal papillary projections of tall columnar epithelium (1,2). On the other hand, the term IPMN of intra/extrahepatic bile duct was introduced and it has a more favorable prognosis compared with conventional cholangiocarcinoma.These tumors ( IPMN of pancreas and IPMN of biliary tract) share many, but not all, clinical, histopathological and genetic features (3,4).…”

Section: Introductionmentioning

confidence: 99%

Intrahepatic Biliary Intraductal Papillary Mucinous Neoplasm With Intermittent Jaundice: Case Report

Cennet

Doğrul

Tırnaksz

et al. 2017

International Surgery

View full text Add to dashboard Cite

Intraductal papillary mucinous neoplasms (IPMNs) represent a relatively new clinical entity. IPMNs have malignant potential which exhibit a broad histological spectrum, ranging from adenoma to invasive carcinoma. Although IPMNs are commonly seen within pancreas, they may develop anywhere within the biliary ductal system and produce mucin which may cause intermittent jaundice. This report details the case of 50 year-old woman presenting with intermittent jaundice who was diagnosed as hepatic IPMN.

show abstract

“…Due to the high risk of malignancy of 60–90% in main-duct and mixed-type IPMN (fig. 1 ), these two entities represent indications for surgical treatment by the time of their diagnosis [ 1 , 2 ]. Surgical therapy must be in accordance with an oncological principle which implies a formal pancreatic resection and lymphadenectomy.…”

Section: Introductionmentioning

confidence: 99%

Main- and Branch-Duct Intraductal Papillary Mucinous Neoplasms: Extent of Surgical Resection

2015

View full text Add to dashboard Cite

Background: Surgical treatment of intraductal papillary mucinous neoplasms (IPMN) requires a differentiated approach regarding indications and extent of resection. Methods: The review summarizes the current literature on indication, timing, and surgical procedures in IPMN. Results: The most important differentiation has to be made between main-duct and branch-duct IPMN as well as mixed-type lesions that biologically mimic main-duct types. In main-duct and mixed-type IPMN, the resection should be indicated by the time of the diagnosis - in accordance with the international consensus guidelines - and should follow oncological principles. Depending on IPMN localization, this implies partial pancreatoduodenectomy, distal pancreatectomy, or total pancreatectomy and includes the corresponding types of lymphadenectomy. Furthermore, branch-duct IPMN > 3 cm or bearing high-risk features (mural nodules in magnetic resonance imaging, computed tomography, or endoscopic ultrasound imaging; symptomatic lesions; elevated tumor markers) are similarly treated. As the risk for malignancy in smaller branch-duct IPMN is lower, the decision for surgical treatment is often individually made - despite the updated 2012 guidelines. In these lesions, limited surgical approaches, including enucleation and central pancreatectomy, are possible. Conclusion: Timely and radical resection of IPMN offers the unique opportunity to prevent pancreatic cancer, and even in malignant IPMN surgery can offer a curative approach with excellent long-term outcome in early stages. A structured imaging follow-up should be considered to recognize IPMN recurrence and metachronous pancreatic cancer as well as gastrointestinal neoplasias by endoscopic surveillance.

show abstract

IPMN: surgical treatment

Cited by 16 publications

References 80 publications

Proteome characterization of human pancreatic cyst fluid from intraductal papillary mucinous neoplasm by liquid chromatography/tandem mass spectrometry

Proteome characterization of human pancreatic cyst fluid from intraductal papillary mucinous neoplasm by liquid chromatography/tandem mass spectrometry

Intrahepatic Biliary Intraductal Papillary Mucinous Neoplasm With Intermittent Jaundice: Case Report

Main- and Branch-Duct Intraductal Papillary Mucinous Neoplasms: Extent of Surgical Resection

Contact Info

Product

Resources

About